Across TCGA pan-cancer cohorts, IGHD2-15 RNA differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of IGHD2-15’s most consistent transcriptional readouts.
The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where IGHD2-15 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types IGHD2-15 is over-expressed in tumor, although a few such as PRAD and READ show the opposite, repressed pattern.
KIRC, LUAD, and ESCA are the cancer types where IGHD2-15 tumor–normal differential expression is most reproducible.
RNA tumor vs normal associations by lineage
Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in IGHD2-15 RNA (log2); positive values indicate higher expression in tumor. p-values are from the differential-expression test.